Abstract
There have been a number of promising recent developments in the prevention of colorectal cancer. This book examines in detail important aspects of the current status of and future prospects for chemoprevention of colorectal tumors, particularly using anti-inflammatory drugs. Research into the mechanisms that lead from early colorectal adenoma to colorectal cancer is discussed. The role and modes of action of available anti-inflammatory drugs, such as aspirin, celecoxib, and sulindac are described and recent data from trials of aspirin are reviewed. In addition, the possible impact of nutritional agents with anti-inflammatory properties is considered, and strategies applicable in those with a high level of genetic risk are evaluated. An important feature of the book is its interdisciplinary perspective, offering highly relevant information for gastroenterologists, internists, general practitioners, oncologists, colorectal and gastroenterological surgeons, and public health practitioners.
Prospects for Chemoprevention of Colorectal Neoplasia—Emerging Role of Anti-Inflammatory Drugs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J et al (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355(9):885–895
Avivi D, Moshkowitz M, Detering E, Arber N (2012) The role of low-dose aspirin in the prevention of colorectal cancer. Expert Opin Ther Targets PMID 22313430 1:s51−s62
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348(10):891–899
Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B et al (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125(2):328–336
Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873–884
Burn J, Bishop DT, Chapman PD et al (2011a) A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 4(5):655–665
Burn J, Gerdes AM, CAPP2 investigators (2011b) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378(9809):2081–2087.
Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS (2005) Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294(8):914–923
Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131–2142
Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS (2008) Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134(1):21–28
Chan AT, Ogino S, Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302(6):649–658
Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM (2012) The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for the prevention of colorectal adenoma. Cancer Prev Res PMID: 22313430 5(1):61–72
Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ et al (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101:256–266
Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316
Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet].Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on 02/02/2011
Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E et al (2003) Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 48:1998–2002
Logan RFA, Grainge MJ, Shepherd VC, Armitage NC, Muir KR (2008) Group uT. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134(1):29–38
Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP et al (2012) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. The Lancet PMID 22440694 376(9754):1741–1750
Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759):31–41
Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348(10):883–890
Schror K (2009) Acetylsalicyclic acid. Blackwell, Germany
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952
Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231(25):232–235
Vane JR (1982) Adventures and excursions in bioassay: the stepping stones to prostaglandins. Nobel lecture, 8 December PMID 6360277
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Chan, A.T., Detering, E. (2013). An Emerging Role for Anti-inflammatory Agents for Chemoprevention. In: Chan, A., Detering, E. (eds) Prospects for Chemoprevention of Colorectal Neoplasia. Recent Results in Cancer Research, vol 191. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-30331-9_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-30331-9_1
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-30330-2
Online ISBN: 978-3-642-30331-9
eBook Packages: MedicineMedicine (R0)